ISAR Score: Can We Predict the Need for Repeat PCI in DES Restenosis?

Score to predict the risk of repeat PCI in DES restenosis.


With the use of drug eluting stents (DES) instent restenosis (ISR) has seen a significant reduction vs. bare metal stents (BMS) restenosis. 

ISAR Score: ¿Podemos predecir necesidad de una nueva angioplastia en reestenosis de los stents liberadores de droga?

The main cause of DES failure is ISR. This entity is difficult to manage because of its high recurrence and reintervention risk. Even though ISR morphology has been classified (also for prognosis purposes) this classification was based on BMS ISR, which makes us question its value for DES. 

In this regard, J.J. Coughlan et all carried out and validated a model to predict the need for repeat PCI in DES ISR, with one-year followup. 

Consecutive patients were enrolled since December 2005 to December 2013 at 2 centers in Germany. Based on the Mehran classification, ISR was classified in 4 groups: four groups: type I: focal; type II: diffuse, within stent; type III: diffuse, within and beyond stent; and type IV: occlusive. 

Primary end point was repeat PCI for recurrent DES-ISR. Other end points included all-cause mortality, acute MI, stent thrombosis and post ISR CABG. 

Read also: Have Complications Related to Balloon Pulmonary Angioplasty Changed Since its Inception?

Retrospectively, patients were randomized 3:1 into training and validation cohorts. Data from 1986 patients treated with PCI for DES-ISR were obtained; 1471 were randomized to the training cohort and 515 to the validation cohort. Mean followup was 7.4 years. Mean age of patients was 69.8 years, 20% were women, 39% diabetic, 25.5% presented as ACS and mean time between first and repeat PCI was 247 days. 65% of cases presented focal ISR, and the most frequent localization was the anterior descending (36.4%), followed by the right coronary (30.3%) and the circumflex (29.3%). 

There was accumulated incidence of repeat revascularization with PCI for DES ISR of 17.7% a year. After logistic regression, there were four independent factors leading to repeat PCI: non-focal ISR pattern, a time interval to ISR of <6 months, ISR of the left circumflex and the presence of moderate/severe calcification in target vessel. 

These variables were used in the ISAR-SCORE (C-statistic modest con HR 0.60, CI 95%:  0.57-0.63), a point was given to each of the above mentioned factors, with a score ranging between 0 and 4. The annual incidence of repeat PCI for DES ISR 0 score was 12.1%, DES ISR 1 was 15.9%, DES ISR 2 was 24.2% and DES ISR ≥3 was 30.5%. Compared against ISR 0, primary end point incidence increased as follows: Score 1 (HR 1.37, CI 95%: 1.04-1.79), 2 (HR 2.27, CI: 95% 1.69-3.07) y ≥3 (HR 3.11, CI 95%: 2.15-4.81). 

Read also: AQCA Study: Pre-PCI Virtual QFR for Planning PCI vs. Conventional Angiography.

ISR score correlated both for ACS (p for trend <0.001) and chronic coronary syndrome (p for trend <0.001). 

Conclusions

This study looked at one of the largest cohorts of DES ISR to predict repeat PCI. Based on the presence of 4 factors, researchers were able to develop the ISAR Score. Even though it has a modest discriminatory power, it would allow to identify patients prone to an aggressive response of the treated vessel in the form of restenosis. Further external validation is still required to assess feasibility in the daily practice. 

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Original Title: Derivation and validation of the ISAR score to predict the risk of repeat percutaneous coronary intervention for recurrent drug-eluting stent restenosis.

Reference: Coughlan, J J et al. “Derivation and validation of the ISAR score to predict the risk of repeat percutaneous coronary intervention for recurrent drug-eluting stent restenosis.” EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology vol. 18,16 e1328-e1338. 3 Apr. 2023, doi:10.4244/EIJ-D-22-00860.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

AHA 2024 | VANISH2 Trial

Cardiac defibrillator implants (CDIs) have been shown to improve survival in patients with ischemic cardiomyopathy and ventricular tachycardia (VT). However, approximately one third of...

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...